- Home
- EDSA vs NEUP Comparison
EDSA vs NEUP Comparison
Compare EDSA & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDSA
- NEUP
- Stock Information
- Founded
- EDSA 2015
- NEUP 1996
- Country
- EDSA Canada
- NEUP United States
- Employees
- EDSA N/A
- NEUP N/A
- Industry
- EDSA Biotechnology: Pharmaceutical Preparations
- NEUP
- Sector
- EDSA Health Care
- NEUP
- Exchange
- EDSA Nasdaq
- NEUP Nasdaq
- Market Cap
- EDSA 13.8M
- NEUP 12.7M
- IPO Year
- EDSA N/A
- NEUP N/A
- Fundamental
- Price
- EDSA $2.03
- NEUP $7.10
- Analyst Decision
- EDSA Strong Buy
- NEUP Strong Buy
- Analyst Count
- EDSA 2
- NEUP 1
- Target Price
- EDSA $13.00
- NEUP $21.00
- AVG Volume (30 Days)
- EDSA 33.4K
- NEUP 24.5K
- Earning Date
- EDSA 08-08-2025
- NEUP 08-15-2025
- Dividend Yield
- EDSA N/A
- NEUP N/A
- EPS Growth
- EDSA N/A
- NEUP N/A
- EPS
- EDSA N/A
- NEUP 0.00
- Revenue
- EDSA N/A
- NEUP $15,662,715.00
- Revenue This Year
- EDSA N/A
- NEUP N/A
- Revenue Next Year
- EDSA N/A
- NEUP N/A
- P/E Ratio
- EDSA N/A
- NEUP $2.29
- Revenue Growth
- EDSA N/A
- NEUP N/A
- 52 Week Low
- EDSA $1.55
- NEUP $2.90
- 52 Week High
- EDSA $5.59
- NEUP $126.00
- Technical
- Relative Strength Index (RSI)
- EDSA 52.89
- NEUP N/A
- Support Level
- EDSA $1.91
- NEUP N/A
- Resistance Level
- EDSA $2.14
- NEUP N/A
- Average True Range (ATR)
- EDSA 0.12
- NEUP 0.00
- MACD
- EDSA 0.02
- NEUP 0.00
- Stochastic Oscillator
- EDSA 64.52
- NEUP 0.00
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.
About NEUP Neuphoria Therapeutics Inc. Common Stock
Neuphoria Therapeutics Inc is a clinical stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder.